Antibody Response in Healthcare Workers before and after the Third Dose of Anti-SARS-CoV-2 Vaccine: A Pilot Study

Alessandra Panico; Giambattista Lobreglio; Francesco Bagordo; Antonella Zizza; Antonella De Donno; Chiara Rosato; Roberta Lazzari; Michele Chicone; Floriano Indino; Virginia Recchia; Pietro Alifano; Tiziana Grassi

doi:10.3390/vaccines10060862

Vaccines (May 2022)

Antibody Response in Healthcare Workers before and after the Third Dose of Anti-SARS-CoV-2 Vaccine: A Pilot Study

Alessandra Panico,
Giambattista Lobreglio,
Francesco Bagordo,
Antonella Zizza,
Antonella De Donno,
Chiara Rosato,
Roberta Lazzari,
Michele Chicone,
Floriano Indino,
Virginia Recchia,
Pietro Alifano,
Tiziana Grassi

Affiliations

Alessandra Panico: Department of Biological and Environmental Science and Technology, University of Salento, 73100 Lecce, Italy
Giambattista Lobreglio: Clinical Pathology and Microbiology Unit, Vito Fazzi General Hospital, 73100 Lecce, Italy
Francesco Bagordo: Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, 70121 Bari, Italy
Antonella Zizza: Institute of Clinical Physiology, National Research Council, 73100 Lecce, Italy
Antonella De Donno: Department of Biological and Environmental Science and Technology, University of Salento, 73100 Lecce, Italy
Chiara Rosato: Clinical Pathology and Microbiology Unit, Vito Fazzi General Hospital, 73100 Lecce, Italy
Roberta Lazzari: Clinical Pathology and Microbiology Unit, Vito Fazzi General Hospital, 73100 Lecce, Italy
Michele Chicone: Clinical Pathology and Microbiology Unit, Vito Fazzi General Hospital, 73100 Lecce, Italy
Floriano Indino: Clinical Pathology and Microbiology Unit, Vito Fazzi General Hospital, 73100 Lecce, Italy
Virginia Recchia: Institute of Clinical Physiology, National Research Council, 73100 Lecce, Italy
Pietro Alifano: Department of Biological and Environmental Science and Technology, University of Salento, 73100 Lecce, Italy
Tiziana Grassi: Department of Biological and Environmental Science and Technology, University of Salento, 73100 Lecce, Italy

DOI: https://doi.org/10.3390/vaccines10060862
Journal volume & issue: Vol. 10, no. 6
p. 862

Abstract

Read online

The SARS-CoV-2 pandemic led to the development of various vaccines. The BNT162b2 mRNA vaccine was the first approved due to its efficacy in eliciting a humoral immunity response after the second dose. However, a decrease in the antibody concentration was observed over time. Therefore, the administration of a third dose was scheduled, primarily for frail people and workers of essential public activities. The aim of this study was to assess the level of antibodies against the spike (S) RBD of SARS-CoV-2 in healthcare workers before and after the third dose of BNT162b2 vaccine, according to sex, age, and the time interval between vaccine doses and tests. All 37 (12 males, 25 females, 19 p < 0.05). This study indicated the benefit of the third dose of BNT162b2 vaccine and its effect on leveling up the humoral immune response.

Published in Vaccines

ISSN: 2076-393X (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine
Website: http://www.mdpi.com/journal/vaccines

About the journal

Abstract

Keywords